TY - JOUR
T1 - Mortality Due to Mitral Regurgitation Among Adults in the United States
T2 - 1999-2018
AU - Parcha, Vibhu
AU - Patel, Nirav
AU - Kalra, Rajat
AU - Suri, Sarabjeet S.
AU - Arora, Garima
AU - Arora, Pankaj
N1 - Publisher Copyright:
© 2020 Mayo Foundation for Medical Education and Research
PY - 2020/12
Y1 - 2020/12
N2 - OBJECTIVE: To evaluate the nationwide trends in mortality due to mitral regurgitation (MR) among American adults from 1999 to 2018.PATIENTS AND METHODS: Trends in mortality due to MR were assessed using retrospective cross-sectional analyses of nationwide mortality data from death certificates of all American residents between January 1, 1999, and December 31, 2018, using the Centers for Disease Control and Prevention Wide-Ranging Online Data for Epidemiologic Research database. Piecewise linear regression was used to evaluate the trends in the overall population and in subgroups.RESULTS: Among 45,982 deaths due to MR during the study period, higher mortality rates were seen in older White females from the western United States. In 1999, the crude and age-adjusted mortality rates were 27.4 (95% CI, 26.3 to 28.4) and 27.5 (95% CI, 26.4 to 28.5) per 1,000,000 persons, respectively. By 2018, these rates declined to 18.0 (95% CI, 17.3 to 18.7) and 17.7 (95% CI, 17.0 to 18.4) per 1,000,000 persons, respectively (P<.001 for trend for both). Crude mortality rates declined from 1999 to 2012 (annual percentage change [APC], -4.1 (95% CI, -4.6 to -3.6) but then increased after 2012 (APC, 2.6 [95% CI, 0.8 to 4.4; P<.001 for change in trend]). The age-adjusted mortality rates declined from 1999 to 2012 (APC, -3.9 [95% CI, -4.4 to -3.4]) but subsequently increased after 2012 (APC, 1.4 [95% CI, -0.4 to 3.2; P<.001 for change in trend]). The observed decrease was consistent across age, sex, race, geographic region, and urbanization subgroups (P<.05 for all).CONCLUSION: Mortality due to MR in American adults declined at an annual rate of approximately 4% until 2012 and has since then increased by about 1.5% annually. These mortality trends warrant further investigation.
AB - OBJECTIVE: To evaluate the nationwide trends in mortality due to mitral regurgitation (MR) among American adults from 1999 to 2018.PATIENTS AND METHODS: Trends in mortality due to MR were assessed using retrospective cross-sectional analyses of nationwide mortality data from death certificates of all American residents between January 1, 1999, and December 31, 2018, using the Centers for Disease Control and Prevention Wide-Ranging Online Data for Epidemiologic Research database. Piecewise linear regression was used to evaluate the trends in the overall population and in subgroups.RESULTS: Among 45,982 deaths due to MR during the study period, higher mortality rates were seen in older White females from the western United States. In 1999, the crude and age-adjusted mortality rates were 27.4 (95% CI, 26.3 to 28.4) and 27.5 (95% CI, 26.4 to 28.5) per 1,000,000 persons, respectively. By 2018, these rates declined to 18.0 (95% CI, 17.3 to 18.7) and 17.7 (95% CI, 17.0 to 18.4) per 1,000,000 persons, respectively (P<.001 for trend for both). Crude mortality rates declined from 1999 to 2012 (annual percentage change [APC], -4.1 (95% CI, -4.6 to -3.6) but then increased after 2012 (APC, 2.6 [95% CI, 0.8 to 4.4; P<.001 for change in trend]). The age-adjusted mortality rates declined from 1999 to 2012 (APC, -3.9 [95% CI, -4.4 to -3.4]) but subsequently increased after 2012 (APC, 1.4 [95% CI, -0.4 to 3.2; P<.001 for change in trend]). The observed decrease was consistent across age, sex, race, geographic region, and urbanization subgroups (P<.05 for all).CONCLUSION: Mortality due to MR in American adults declined at an annual rate of approximately 4% until 2012 and has since then increased by about 1.5% annually. These mortality trends warrant further investigation.
UR - http://www.scopus.com/inward/record.url?scp=85096543906&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85096543906&partnerID=8YFLogxK
U2 - 10.1016/j.mayocp.2020.08.039
DO - 10.1016/j.mayocp.2020.08.039
M3 - Article
C2 - 33276836
AN - SCOPUS:85096543906
SN - 0025-6196
VL - 95
SP - 2633
EP - 2643
JO - Mayo Clinic Proceedings
JF - Mayo Clinic Proceedings
IS - 12
ER -